Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
1(33.3%)
Phase 3
1(33.3%)
Phase 4
1(33.3%)
3Total
Phase 2(1)
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06497699Phase 4Completed

A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery

Role: lead

NCT06429306Phase 3Completed

Study of Dexycu in Treating Intraocular Inflammation

Role: lead

NCT06435182Phase 2Completed

Study of OT202 in Treating Moderate to Severe Dry Eye

Role: lead

All 3 trials loaded